Home > Cardiology > ESC 2021 > Best of the Hotline Sessions > Empagliflozin: First drug with clear benefit in HFpEF patients

Empagliflozin: First drug with clear benefit in HFpEF patients

Presented By
Prof. Stefan Anker, Charité University Hospital, Germany
ESC 2021
Phase 3, EMPEROR-Preserved
As the first positive study about a treatment drug in heart failure with preserved ejection fraction (HFpEF), EMPEROR-Preserved is considered a landmark trial. Besides a relevant 21% reduction in the primary composite outcome, key secondary endpoints results were also significant [1,2]. “We are about to have one of the most exciting clinical trials, I think, we’ve seen in a long time presented here in this Hotline-session at the ESC 2021–Digital experience and I have to say that I cannot think of any trial been more anticipated than the EMPEROR-Preserved trial,” Prof. John McMurray (University of Glasgow, Scotland) introduced the EMPEROR-Preserved (NCT03057951) [1]. The trial aimed to assess empagliflozin as add-on to standard of care for HFpEF patients. It included 5,988 patients with HFpEF who had been hospitalised for HF within the last 12 months or were diagnos...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on